Elvina Almuradova/LinkedIn
Apr 14, 2025, 08:06
Elvina Almuradova: The recent FDA approval of larotrectinib reminds that NTRK fusions can occur across many tumor types
Elvina Almuradova, Ambassador at European School of Oncology, shared a post on X:
“The recent FDA approval of larotrectinib reminds us of something critical:
NTRK fusions can occur across many tumor types, yet we often don’t test for them.
By missing the fusion, we miss the opportunity and that makes things harder than they need to be!”
More posts featuring Elvina Almuradova.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 9, 2025, 18:18
Sep 9, 2025, 17:59
Sep 9, 2025, 17:43
Sep 9, 2025, 16:51
Sep 9, 2025, 15:59